<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 7; Issue 2</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(Mar-Apr, 2026)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Lamotrigine-Induced Stevens-Johnson Syndrome in a Young Female Patient with Atypical Anorexia Nervosa and Major Depression: A Case Report</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>7</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Miguel</FirstName>
          <LastName>Almeida-Pérez</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Elizabeth</FirstName>
          <LastName>Valdivia-Marquez</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Karina</FirstName>
          <LastName>García-Pérez</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Deysi</FirstName>
          <LastName>Carhuamaca-Lino</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>David</FirstName>
          <LastName>Gómez-Pereda</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Stevens-Johnson Syndrome (SJS) is a rare, severe cutaneous adverse reaction often triggered by medications such as lamotrigine. We present the case of a 21-year-old female with Atypical Anorexia Nervosa and Major Depression who developed SJS thirty days after initiating a psychopharmacological regimen comprising lamotrigine, fluoxetine, and olanzapine. Clinical examination revealed extensive mucocutaneous lesions, including hemorrhagic cheilitis, palpebral ulcers, and targetoid lesions. The condition resolved following immediate drug discontinuation and systemic corticosteroid treatment. This case underscores the risks of rapid titration and polypharmacy in patients with Atypical Anorexia Nervosa, where metabolic instability may alter drug metabolism. Clinicians must exercise heightened vigilance and strictly adhere to slow titration schedules in this vulnerable population.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Stevens-Johnson Syndrome,Lamotrigine,Anorexia Nervosa,Major Depression,Polypharmacy,Drug Hypersensitivity</Keywords>
      <URLs>
        <Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=16167&amp;title=Lamotrigine-Induced Stevens-Johnson Syndrome in a Young Female Patient with Atypical Anorexia Nervosa and Major Depression: A Case Report</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-121.&#13;
&#13;
Chung WH, Hung SI. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Dermatol Sci 2012; 66: 190-196.&#13;
&#13;
Edinoff AN, Nguyen LH, Fitz-Gerald MJ, Crane E, Lewis K, Pierre SS, et al. Lamotrigine and Stevens-Johnson Syndrome prevention. Psychopharmacol Bull 2021; 51: 96-114.&#13;
&#13;
Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010; 5: 39.&#13;
&#13;
McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity. N Engl J Med 2011; 364: 1134-1143.&#13;
&#13;
Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study. J Invest Dermatol 2018; 138: 2315-2321.&#13;
&#13;
Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-1138.&#13;
&#13;
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.&#13;
&#13;
Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607.&#13;
&#13;
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, classification, clinical features, etiology, and immunopathogenesis. J Am Acad Dermatol 2013; 69: 173.e1-173.e13.&#13;
&#13;
Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100: 4-22.&#13;
&#13;
Stern RS. Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Med Assoc 2014; 312: 1590-1591.&#13;
&#13;
Winston AP. The clinical biochemistry of anorexia nervosa. Ann Clin Biochem 2012; 49: 132-143.&#13;
&#13;
Zenger F, Russmann S, Junker E, Wuthrich C, Bui MH, Lauterburg BH. Decreased glutathione in patients with anorexia nervosa: Risk factor for toxic liver injury? Eur J Clin Nutr 2004; 58: 238-243.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>